百利天恒：注射用BL-M24D1(ADC)药物临床试验获批准

Core Viewpoint - The company, Baile Tianheng (688506.SH), has received formal approval from the National Medical Products Administration (NMPA) for the clinical trial of its innovative biopharmaceutical, BL-M24D1 (ADC) [1] Group 1: Product Development - BL-M24D1 is an ADC drug that incorporates a new generation toxin, developed independently by the company [1] - The drug is part of the same small molecule technology platform as BL-B16D1 and BL-M17D1, sharing the same "linker + toxin" platform [1] - The indications for BL-M24D1 include relapsed or refractory hematologic malignancies and advanced solid tumors [1]